McKesson Corporation

Analyst Ratings Synthesis

Consensus is Buy across all 17 analysts, with the available mean price target at $950; consensus low and high targets were not supplied, so the overall spread cannot be measured. Among explicitly reported targets, Citi is most bullish at $945, while Wells Fargo is least bullish at $812; Barclays sits at $925. Revisions during the supplied week are not reported, but the recent direction has been downward: Barclays cut its target to $925 from $1,050 on June 10, Citi cut to $945 from $975, and Simply Wall St. described a slight trimming of its estimate. The substantive disagreement centers on whether specialty and oncology growth plus operating efficiency can outweigh GLP-1 pricing, policy, tariff and funding risks.

• McKesson Q1 27 Earnings Conference Call At 4:30 PM ET
• RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up
• What's in Store for These 4 Healthcare Companies This Earnings Season?
• BTSG Drops 18.1% in One Week as Growth Meets Fresh Valuation Risks
• Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up